<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890134</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISESADS INCP (RB 15.007)</org_study_id>
    <nct_id>NCT02890134</nct_id>
  </id_info>
  <brief_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort</brief_title>
  <acronym>PRECISESADSI</acronym>
  <official_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrys Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Cántabro de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>August Pi Sunyer Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quartz Bio S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cyprus Foundation for Muscular Dystrophy Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Network for Design and Translation of Advanced Therapies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known&#xD;
      today are a group of chronic inflammatory conditions with autoimmune aetiology with few&#xD;
      treatment options and difficult diagnosis.Brest team contribute to performe a new&#xD;
      classification of the following systemic autoimmune diseases in a European Union's Seventh&#xD;
      Framework Programme. The aim of this research consiteis to reclassify the individuals&#xD;
      affected by SADs into molecular clusters instead of clinical entities through the&#xD;
      determination of molecular profiles using several &quot;Omics&quot; techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the PRECISESADS IMI project is to reclassify the individuals&#xD;
      affected by SADs into clusters of molecular, instead of clinical entities through the&#xD;
      determination of molecular profiles using several &quot;-omics&quot; techniques.&#xD;
&#xD;
      The identification of the clusters relies on a cross sectional (CS) cohort/protocol where&#xD;
      2666 individuals (2000 patients and 666 controls) including a sub-study of 288 deeply&#xD;
      characterized individuals (240 patients and 48 controls) are to be recruited.&#xD;
&#xD;
      In parallel a longitudinal inception cohort/protocol will be started in order to further&#xD;
      explore the clinical relevance of the identified clusters and their evolution over time.&#xD;
&#xD;
      The objectives of the CS study and sub-study are:&#xD;
&#xD;
        1. To identify a systemic taxonomy for patients with SADs by producing the following data&#xD;
           in individuals with SADs and controls: genetic, epigenomic, transcriptomic, flow&#xD;
           cytometric (from peripheral blood mononuclear cells (PBMCs)), metabolomics and proteomic&#xD;
           in plasma and urine, exosome analysis, classical serology (antibodies and&#xD;
           autoantibodies), and clinical data.&#xD;
&#xD;
        2. To better characterize individual SADs at the omics level.&#xD;
&#xD;
        3. To perform clustering analyses to determine the groups of individuals who,&#xD;
           differentially from other groups, share specific molecular features (precision&#xD;
           medicine).&#xD;
&#xD;
        4. A deeper analysis will be done in a substudy of 288 individuals.&#xD;
&#xD;
      The clustering process will be data-driven with the aim to find the most homogenous and&#xD;
      differentiated clusters of diseases that clearly separate differentiate individuals from&#xD;
      controls and other patient clusters.&#xD;
&#xD;
      Aims of the Inception cohort:&#xD;
&#xD;
      Specifically, this inception cohort aims at:&#xD;
&#xD;
        1. assign individuals newly diagnosed with an systemic autoimmune disease (SAD) to any of&#xD;
           the reclassification clusters discovered in the CS study,&#xD;
&#xD;
        2. to study the development and modifications of OMICS signatures/clusters occurring in&#xD;
           each individual patient in the course of the disease, including the impact of treatment&#xD;
           on their individual pattern, and&#xD;
&#xD;
        3. to perform deep (thorough) OMICs studies to compare their patterns of OMICS as a group,&#xD;
           with the patterns obtained in the CS cohort.&#xD;
&#xD;
      The inception cohort will have patient follow up and sample collection at baseline, month&#xD;
      6(±1 month) and month 18 (±1 month).&#xD;
&#xD;
      As the newly diagnosed patients we plan to recruit will have minimum or no treatment, we will&#xD;
      identify differences and similitudes to patients from the cross-sectional study that have&#xD;
      undergone long-term treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Gene expression will be done using commercial gene expression microarrays in total blood from all samples using the RNA Paxgene tube.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.</measure>
    <time_frame>24 hours</time_frame>
    <description>9 optimized panels of antibodies will be used to determine cell subpopulations in peripheral blood (including very minor cell populations).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotyping</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping will be done using a whole genome array.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite determination</measure>
    <time_frame>2 years</time_frame>
    <description>Metabolite determination in plasma and urine using Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exosome isolation from plasma and urine</measure>
    <time_frame>2 years</time_frame>
    <description>set up of the methodology for isolating exosomes in these bodily fluids for gene expression analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profile determination</measure>
    <time_frame>2 years</time_frame>
    <description>88 different cytokines will be assessed with Luminex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>routine autoantibodies in serum</measure>
    <time_frame>2 years</time_frame>
    <description>set of serum autoantibodies will be determined in a European validated laboratory. Also, they will perform detection of antibodies against small lipid moieties i.e.antiphosphorylcholine),lupus anticoagulant and complement proteins in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene methylation in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Methylation analysis will be done using the methylome 450k array using the DNA obtained from total blood. MicroRNA gene expression arrays using total blood.</description>
  </primary_outcome>
  <enrollment type="Actual">215</enrollment>
  <condition>Systemic Autoimmune Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with systemic autoimmune diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  · Aged 18 years or older at the time of consent&#xD;
&#xD;
               -  Diagnosed according to prevailing criteria for one of the following systemic&#xD;
                  autoimmune diseases (see Annex 2)&#xD;
&#xD;
                    -  Rheumatoid arthritis (RA)&#xD;
&#xD;
                    -  Scleroderma or systemic sclerosis (SSc)&#xD;
&#xD;
                    -  Primary Sjögren's syndrome (SjS)&#xD;
&#xD;
                    -  Systemic lupus erythematosus (SLE)&#xD;
&#xD;
                    -  Primary antiphospholipid syndrome (PAPS)&#xD;
&#xD;
                    -  Mixed Connective Tissue Disease (MCTD)&#xD;
&#xD;
                    -  Patients with undifferentiated connective tissue disease (UCTD) for over 1&#xD;
                       year and that do not fulfill the diagnosis of any of the above diseases.&#xD;
&#xD;
               -  Signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  · Patients unable to understand the procedures related to the protocol should not be&#xD;
             included. The study is voluntary and patients must be able to give their informed&#xD;
             consent.&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Neonatal lupus&#xD;
&#xD;
               -  Drug-induced lupus&#xD;
&#xD;
               -  Patients whose condition is so serious that they cannot take part in the study&#xD;
&#xD;
               -  Severe nephrotic syndrome with proteinuria &gt;=3,5 g/day&#xD;
&#xD;
               -  Patients with stable doses of steroids &gt;15mg/day for the last 3 months or with IV&#xD;
                  corticosteroids in the last 3 months&#xD;
&#xD;
               -  Patients under immunosuppressants for the last 3 months prior to recruitment&#xD;
                  with:&#xD;
&#xD;
                    -  Methotrexate ≥25mg/week&#xD;
&#xD;
                    -  Azathioprine ≥2.5mg/kg/day&#xD;
&#xD;
                    -  Cyclosporine A &gt; 3mg/kg/day&#xD;
&#xD;
                    -  Mycophenolate Mofetil &gt; 2gr/day&#xD;
&#xD;
               -  Treatment with cyclophosphamide (any dose or route of administration) or&#xD;
                  Belimumab in the past 6 months&#xD;
&#xD;
               -  Patients with combined therapy of two or more immunosuppressants&#xD;
&#xD;
               -  Patients on depletative therapy such as Rituximab in the last year&#xD;
&#xD;
               -  Patients receiving experimental&#xD;
&#xD;
               -  Overlap syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Alarcon</last_name>
    <role>Study Director</role>
    <affiliation>Fundación Pública Andaluza Progreso y Salud (PHFSpain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université catholique de Louvain - Cliniques Universitaires Saint-Luc (UCL)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía Andaluz de Salud</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio Servicio Andaluz de Salud</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves Granada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitaux Universitaires de Géneve (UNIGE)</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SADs</keyword>
  <keyword>Molecular Reclassification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

